Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5330628 | 0.74 | KMT2A (0.49) | BTKCTSKNFKB1NFKB2RELA | |
| SCHEMBL420235 | 0.73 | BTK (0.46) | EPHX1BTKGAACTSKCTSS | |
| SCHEMBL17688410 | 0.73 | BTK (0.46) | EPHX1BTKGAACTSKCTSS | |
| SCHEMBL3575502 | 0.73 | BTK (0.42) | EPHX1BTKGAACTSKNFKB1 | |
| SCHEMBL3077329 | 0.72 | BTK (0.38) | EPHX1BTKGAACTSKCTSS | |
| SCHEMBL3080169 | 0.72 | — | — | |
| SCHEMBL2493608 | 0.71 | BTK (0.46) | EPHX1BTKGAACTSKNFKB1 | |
| SCHEMBL2496332 | 0.71 | CACNA1B (0.41) | KMT2AL3MBTL1KDM1AMAOB | |
| SCHEMBL415860 | 0.70 | BTK (0.43) | EPHX1BTKGAACTSKCTSS | |
| SCHEMBL5800481 | 0.70 | BTK (0.44) | EPHX1BTKGAACTSKNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150541-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-8486970-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100227866-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227866-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | EPHX1 2650/4885BTK 792/4885GAA 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.